---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-137731"
form_type: "8-K"
ticker: "PLRX"
cik: "0001746473"
company_name: "PLIANT THERAPEUTICS, INC."
filed_at: "2024-05-14T23:59:59+00:00"
generated_at: "2026-06-02T01:00:49.316834+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Pliant Therapeutics: Phase 2a trial of bexotegrast shows reduced lung collagen and improved lung function in IPF

## Summary
- Bexotegrast 160 mg reduced total lung collagen on PET imaging vs. increased collagen on placebo over 12 weeks.
- Treated patients showed improvements in forced vital capacity (FVC) and cough severity at all timepoints vs. placebo.
- No drug-related serious adverse events or discontinuations reported; most TEAEs mild.
- Trial enrolled 10 patients (7 active, 3 placebo); 8 on standard of care (mostly nintedanib).
- Biomarkers integrin beta-6 and PRO-C3 reduced in bexotegrast arm vs. placebo at weeks 4 and 12.

## SEC filing metadata
- accession: 0001193125-24-137731
- form_type: 8-K
- ticker: PLRX
- cik: 0001746473
- company_name: PLIANT THERAPEUTICS, INC.
- filed_at: 2024-05-14T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1746473/000119312524137731/0001193125-24-137731-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1746473/000119312524137731/d798874d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-137731
- JSON: https://secwatch.observer/filing/0001193125-24-137731.json
- Plain text: https://secwatch.observer/filing/0001193125-24-137731.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.